Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

WSW, NY, August 10th, 2026, FinanceWire

Checkpoint inhibitors are drugs that remove the "brakes" cancer puts on the immune system, letting the body's own defenses attack tumors. They are the biggest success story in modern oncology: Merck's Keytruda (pembrolizumab) alone generated over $30 billion in 2025. But pancreatic cancer has remained stubbornly resistant. Silexion Therapeutics (NASDAQ: SLXN) just released preclinical data suggesting its lead candidate, SIL204, may change that, not by competing with checkpoint inhibitors, but by potentially making them work where they currently don't.

In recently reported studies, SIL204 produced statistically significant changes across three immune pathways in KRAS-mutant cancer cells. It upregulated FAS (CD95), a cell-surface "death receptor" that allows immune cells to trigger cancer cell death. It downregulated HLA-G, a molecule tumors use to tell the immune system to stand down, essentially a "do not attack" signal. And, as previously reported in May 2026, it upregulated MHC-I, the molecular ID tag that lets immune cells distinguish cancer from healthy tissue.

The effect is three-pronged: SIL204 appears to make tumors simultaneously more visible, more vulnerable to immune attack, and less able to suppress the immune response. If that translates from lab to clinic, it could be the immune priming checkpoint inhibitors need to work where they currently do not.

The findings span three KRAS mutations (G12D, G12V, G12C) across both pancreatic and non-small cell lung cancer cell lines. FAS levels roughly doubled in KRAS G12D-mutant pancreatic cancer cells (P<0.0001, meaning less than a 0.01% chance of being random). HLA-G reductions were significant at 24 and 72 hours in KRAS G12C-mutant NSCLC cells (P<0.001 and P<0.01). Combined with prior MHC-I data, the immune-modulatory effects now span four distinct KRAS mutations.

"SIL204 is producing this coordinated immune-sensitizing effect across multiple KRAS mutations and both of the largest KRAS-driven tumor types," said Ilan Hadar, Chairman and CEO of Silexion. "We believe this profile supports the rationale for further evaluation of SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies, particularly in indications like pancreatic cancer where these agents have historically shown limited single-agent efficacy."

The timing is notable. Recent research from MD Anderson Cancer Center and studies in Cancer Cell and Cancer Discovery has shown that combining KRAS inhibition with anti-PD-1 agents can produce sustained tumor regression. Research in Developmental Cell demonstrated that eliminating oncogenic KRAS in pancreatic cancer mouse models restored FAS expression, enabling immune cells to eradicate tumors. Silexion's data suggest SIL204 may trigger the same FAS restoration through RNA interference.

HLA-G is also attracting pharma attention, with multiple programs now in clinical trials targeting it directly. SIL204's approach is different: it reduces HLA-G as a secondary effect of silencing KRAS, rather than targeting HLA-G head-on. That could give it a differentiated profile, addressing multiple immune pathways simultaneously instead of just one.

These findings arrive as Silexion advances SIL204 into clinical testing. The company initiated its Phase 2/3 trial at Tel Aviv Sourasky Medical Center in late July 2026, evaluating SIL204 combined with standard chemotherapy, not immunotherapy, in locally advanced pancreatic cancer. The immuno-oncology data now emerging could inform future combination strategies with checkpoint inhibitors.

The market context is hard to ignore. KRAS mutations appear in roughly 90% of pancreatic cancers and 30-35% of lung adenocarcinomas. The pancreatic cancer treatment market alone is projected to exceed $7 billion by 2030 (Polaris Market Research), yet the disease carries a five-year survival rate of just 13% (Pancreatic Cancer Action Network). Big pharma is already betting heavily on KRAS: Bristol-Myers Squibb acquired Mirati Therapeutics for $4.8 billion in 2023, and AbbVie signed a deal worth up to $1.45 billion for Kestrel Therapeutics' KRAS programs. Any approach that could make these immunologically "cold" tumors responsive to checkpoint inhibitors is entering a space where large pharma is actively deploying capital.

SIL204 has not been tested in humans alongside a checkpoint inhibitor, and translating cell-line signals into clinical benefit remains a long path. But the data provide a biological rationale. If SIL204 can restore antigen presentation, increase susceptibility to immune killing, and reduce checkpoint activity in KRAS-driven tumors, it may be the upstream sensitizer that eventually makes Keytruda work in pancreatic cancer. For a micro-cap company at the intersection of KRAS targeting and immunotherapy sensitization, two of the hottest areas in oncology right ow, the next 12 to 18 months of clinical data will be worth watching.

Recent News Highlights from Silexion (NASDAQ: NVCT)

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Read this next >> AbCellera Stock Jumps 33% on a Positive Menopause Trial (NASDAQ: ABCDL)

This report was originally published on The Finance Herald, on July 5, 2026

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Silexion Therapeutics Corp. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article has not been reviewed or approved by the Issuer prior to publication and should not be considered an official communication of the Issuer. Silexion is subject to numerous risks including its ability to maintain its listing on the Nasdaq, its ability to finance the above mentioned trials, and more, and there is no guarantee the trial will be a success or even that the company will be able to sufficiently fund it.

Contact